H.H. Van Acker
University of Antwerp
ImmunologyDendritic cellCancer immunotherapyBiologyImmune system
What is this?
Publications 2
#1T.J. van EeH-Index: 1
#2H.H. Van AckerH-Index: 2
Last. I.J.M. de VriesH-Index: 57
view all 8 authors...
Dendritic cell (DC) vaccines show promising effects in cancer immunotherapy. However, their efficacy is affected by a number of factors, including (1) the quality of the DC vaccine and (2) tumor immune evasion. The recently characterized BDCA1+CD14+ immunosuppressive cells combine both aspects; their presence in DC vaccines may directly hamper vaccine efficacy, whereas, in patients, BDCA1+CD14+ cells may suppress the induced immune response in an antigen-specific manner systemically and at the t...
3 CitationsSource
#1J.J.P. van Beek (Radboud University Nijmegen)H-Index: 3
#2Gorris (Radboud University Nijmegen)H-Index: 1
Last. Ghaith Bakdash (Radboud University Nijmegen)H-Index: 7
view all 8 authors...
ABSTRACTHuman blood dendritic cells (DCs) hold great potential for use in anticancer immunotherapies. CD1c+ myeloid DCs and plasmacytoid DCs (pDCs) have been successfully utilized in clinical vaccination trials against melanoma. We hypothesize that combining both DC subsets in a single vaccine can further improve vaccine efficacy. Here, we have determined the potential synergy between the two subsets in vitro on the level of maturation, cytokine expression, and effector cell induction. Toll-like...
10 CitationsSource